Business Context and Reporting Period
This Form 8-K Current Report was filed by Indivior Pharmaceuticals, Inc. on March 17, 2026. The filing primarily announces the entry into a material definitive agreement regarding a new debt offering and the termination of a prior debt agreement.
Key Financial Metrics and Transaction Details
- Convertible Notes Issuance: The Company issued $500,000,000 principal amount of 0.625% Convertible Senior Notes due 2031. This total includes $50,000,000 issued pursuant to the full exercise of an over-allotment option by initial purchasers.
- Interest Rate: 0.625% per annum, payable semi-annually in arrears beginning September 15, 2026.
- Maturity Date: March 15, 2031.
- Conversion Terms: Initial conversion rate is 24.0033 shares per $1,000 principal amount (approx. $41.66 per share), representing a 35.0% premium over the March 12, 2026 stock price. Maximum potential shares upon conversion are approximately 16,202,200.
- Debt Repayment: Proceeds from the offering were used to prepay all outstanding principal, accrued interest, and fees under a Note Purchase Agreement originally dated November 4, 2024.
- Liquidity and Cash Flow: The filing does not provide specific cash flow statements, balance sheet totals, or liquidity ratios. It only confirms the use of proceeds to retire prior debt.
Material Changes Versus Prior Period
The primary material change is the restructuring of the Company's debt profile. The Company has replaced a prior credit facility (Note Purchase Agreement) with a new long-term convertible note structure. This action eliminates the obligations under the 2024 Note Purchase Agreement while adding $500 million in senior unsecured obligations maturing in 2031.
Guidance, Outlook, Risks, and Unusual Items
- Redemption Rights: The Company may redeem the Notes on or after March 20, 2029, if the stock price exceeds 130% of the conversion price for a specified period.
- Make-Whole Provisions: In the event of a "Make-Whole Fundamental Change" or if the Company calls the Notes for redemption, the conversion rate may be increased.
- Repurchase Rights: Upon a "Fundamental Change" (e.g., business combination, liquidation, de-listing), noteholders may require the Company to repurchase the Notes at par plus accrued interest.
- Events of Default: Includes payment defaults, failure to deliver conversion consideration, bankruptcy, and defaults on other indebtedness exceeding $55,000,000.
- Unusual Items: The filing notes that the Notes were issued in a private placement to qualified institutional buyers under Rule 144A and Section 4(a)(2) of the Securities Act.
Investor Verification Checklist
- Verify the exact amount of cash proceeds net of issuance costs and the specific impact on the Company's current liquidity position.
- Confirm the terms of the terminated Note Purchase Agreement to understand the cost savings or penalties associated with the early prepayment.
- Review the Indenture (Exhibit 4.1) for specific covenants that may restrict future operations or additional debt issuance.
- Assess the dilution impact of the potential issuance of up to 16,202,200 shares of common stock upon conversion.
- Monitor the Company's stock price relative to the $41.66 conversion price to evaluate the likelihood of conversion or redemption.